头颈癌患者接受免疫治疗情况的差异
这项回顾性队列研究纳入4860例65岁及以上头颈鳞状细胞癌(HNSCC)患者,评估临床与非临床因素与接受免疫治疗的关系。多变量logistic回归显示,白人患者接受免疫治疗的调整比值比(AOR)为1.80(95%CI 1.30-2.48),非口咽癌较口咽癌AOR为1.29(95%CI 1.05-1.59),晚期较局部病变AOR为2.39(95%CI 1.71-3.34)。作者认为白人患者可能更可能接受免疫治疗。
要点
- 4860例患者中552例(11.4%)接受了免疫治疗
- 白人患者接受免疫治疗的AOR为1.80(95%CI 1.30-2.48),高于其他种族
- 晚期病变较局部病变AOR为2.39(95%CI 1.71-3.34),非口咽癌较口咽癌AOR为1.29(95%CI 1.05-1.59)
核心结论
- 作者认为,在老年HNSCC患者中,白人患者可能更可能接受免疫治疗。
- 作者认为,公平获得免疫治疗和其他治疗选择将减少癌症相关健康差异并改善HNSCC患者生存。
研究设计与样本
- 回顾性队列研究,纳入社区肿瘤诊疗机构中65岁及以上诊断为HNSCC的患者4860例。
- 评估2017年1月1日至2022年4月30日期间Navigating Cancer的电子健康记录。
- 采用多变量logistic回归分析临床因素(肿瘤分期[局部 vs 晚期]和解剖亚部位[口咽 vs 非口咽])与非临床因素(年龄、吸烟史、种族和民族、性别、婚姻状况)与接受免疫治疗的关系。
主要发现
- 研究队列4860例患者中,3593例(73.9%)为男性;4230例(87.0%)为白人,630例(13.0%)为其他种族。
- 552例患者(11.4%)接受了免疫治疗。
- 调整协变量后,白人HNSCC患者接受免疫治疗的调整比值比(AOR)为1.80(95%CI 1.30-2.48),高于其他种族患者。
- 基于年龄、性别或吸烟史,接受免疫治疗的比值比无统计学显著差异。
- 非口咽癌患者较口咽癌患者更可能接受免疫治疗(AOR 1.29,95%CI 1.05-1.59);晚期病变患者较局部病变患者更可能接受免疫治疗(AOR 2.39,95%CI 1.71-3.34)。
关键数值与推荐
- 白人患者接受免疫治疗的AOR为1.80(95%CI 1.30-2.48),对照为其他种族患者。
- 非口咽癌患者接受免疫治疗的AOR为1.29(95%CI 1.05-1.59),对照为口咽癌患者。
- 晚期病变患者接受免疫治疗的AOR为2.39(95%CI 1.71-3.34),对照为局部病变患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The US Food and Drug Administration approved immune checkpoint inhibitors (immunotherapy) for select cases of head and neck squamous cell carcinoma (HNSCC) in 2016. However, it is unclear whether there are clinical or sociodemographic differences among patients receiving immunotherapy as part of their care. Given the known disparities in head and neck cancer care, we hypothesized that there are differences in receipt of immunotherapy among patients with HNSCC based on clinical and nonclinical characteristics. OBJECTIVE: To characterize clinical and nonclinical factors associated with receipt of immunotherapy among older patients with HNSCC. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients 65 years or older diagnosed with HNSCC (n = 4860) in a community oncology care setting. Electronic health records from Navigating Cancer were assessed from January 1, 2017, to April 30, 2022. MAIN OUTCOMES AND MEASURES: Multivariable logistic regression was used to characterize clinical (tumor stage [localized vs advanced] and anatomical subsite [oropharyngeal vs nonoropharyngeal]) and nonclinical (age, smoking history, race and ethnicity, sex, and marital status) factors associated with receipt of immunotherapy. RESULTS: In the study cohort of 4860 patients, 3593 (73.9%) were men; 4230 (87.0%) were White and 630 (13.0%) were of other races. A total of 552 patients (11.4%) had received immunotherapy. After adjusting for covariates, in the final model, White patients with HNSCC had 80% increased odds of receiving immunotherapy (adjusted odds ratio [AOR], 1.80 [95% CI, 1.30-2.48]) compared with patients of other races. There were no statistically significant differences in the odds of receiving immunotherapy based on age, sex, or smoking history. Patients with nonoropharyngeal disease were significantly more likely to receive immunotherapy than those with oropharyngeal cancer (AOR, 1.29 [95% CI, 1.05-1.59]), as were those with advanced compared with local disease (AOR, 2.39 [95% CI, 1.71-3.34]). CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that among older patients with HNSCC, White patients may be more likely to receive immunotherapy as part of their care. Equitable access to immunotherapy and other treatment options will reduce cancer-related health disparities and improve survival of patients with HNSCC.
引用
- Ramkumar SP, Bhardwaj A, Patel A, et al. Differences in Receipt of Immunotherapy Treatment Among Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg. 2023. PMID: 37651149. doi:10.1001/jamaoto.2023.2420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。